{"meta":{"query_hash":"4f86e50144c2","filters":{"venue":"Cancer Urology"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4f86e50144c2","api":"https://metacan.xera.ac/api/v1/cohort?venue=Cancer+Urology"},"results":[{"id":"W2813181757","doi":"10.17650/1726-9776-2018-14-2-156-161","title":"Evaluation of radiation cystitis treatment efficacy with glycosaminoglycan replenishment therapy","year":2018,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Urological Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Sodium hyaluronate; Interstitial cystitis; Hyaluronic acid; Radiation therapy; Glycosaminoglycan; Urology; Chondroitin sulfate; Surgery; Internal medicine; Urinary system","score_opus":0.06409684998491752,"score_gpt":0.35732643856591983,"score_spread":0.29322958858100234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2813181757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925775,0.005709258,0.0002801604,0.000059751215,0.00004212893,0.00018918421,0.000104755105,0.000009017093,0.001028227],"genre_scores_gemma":[0.9970079,0.0016506488,0.00049577677,0.000035554214,0.000072117036,0.00013609802,0.00015417663,0.0000021480353,0.00044550796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99927634,0.000308728,0.00008866066,0.0000975778,0.00015021097,0.00007852404],"domain_scores_gemma":[0.9990588,0.00032536688,0.00024238178,0.00006558013,0.00013854993,0.00016945715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011613214,0.00023070065,0.0006818807,0.00036770047,0.0001823308,0.00018935163,0.0001993796,0.00030814027,0.0013756808],"category_scores_gemma":[0.0013329472,0.00008821329,0.000584003,0.00025847447,0.00031970246,0.000300076,0.000145312,0.00034683474,0.00012416519],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20296586,0.044131253,0.25177255,0.0034837208,0.0017156749,0.0007464452,0.0007773832,0.0019248844,0.06703475,0.00041908695,0.00095818774,0.42407015],"study_design_scores_gemma":[0.0034826477,0.6199939,0.32879797,0.00025300583,0.0018762043,0.0009813189,0.0004457538,0.0013246346,0.037443206,0.00016876144,0.005177556,0.000055142333],"about_ca_topic_score_codex":0.00016913927,"about_ca_topic_score_gemma":0.0002507066,"teacher_disagreement_score":0.0013756808,"about_ca_system_score_codex":0.00016897373,"about_ca_system_score_gemma":0.0003153449,"threshold_uncertainty_score":0.006141722},"labels":[],"label_agreement":null},{"id":"W4280630044","doi":"10.17650/1726-9776-2022-18-1-77-89","title":"Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison","year":2022,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Oncology; Internal medicine; Urology; Cancer; Adverse effect","score_opus":0.05150558099593017,"score_gpt":0.3567398578961358,"score_spread":0.30523427690020566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280630044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823826,0.011778323,0.00083771534,0.0002484355,0.00040097086,0.00077153207,0.0012798315,0.000053224187,0.0022472905],"genre_scores_gemma":[0.99637586,0.0016008756,0.00051227456,0.00012063967,0.00013083777,0.00023766157,0.00037758154,0.000008552558,0.00063556636],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959311,0.0030035614,0.00027746762,0.00029102855,0.000290846,0.00020597041],"domain_scores_gemma":[0.9976095,0.0011909093,0.0007086037,0.00020415513,0.00009924055,0.00018773031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025040528,0.0012636742,0.0021567044,0.00050542114,0.00024038284,0.0007561229,0.000799456,0.00091359246,0.005295883],"category_scores_gemma":[0.005651418,0.00050570135,0.003900712,0.0005758524,0.0005326691,0.00089049566,0.0007243,0.0017307773,0.00037618593],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96030116,0.0013230314,0.0037875564,0.001199005,0.015711505,0.000042335785,0.00006199264,0.0007046735,0.0009881732,0.00022642646,0.00031800845,0.015336197],"study_design_scores_gemma":[0.7385602,0.1576759,0.05809213,0.00025455753,0.035627447,0.0002486415,0.0001972279,0.0042190463,0.0017627357,0.00096588425,0.0022851329,0.000111131405],"about_ca_topic_score_codex":0.0029419917,"about_ca_topic_score_gemma":0.0037454169,"teacher_disagreement_score":0.005295883,"about_ca_system_score_codex":0.0009156578,"about_ca_system_score_gemma":0.0005908853,"threshold_uncertainty_score":0.017716467},"labels":[],"label_agreement":null},{"id":"W4292002773","doi":"10.17650/1726-9776-2022-18-2-39-57","title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Lenvatinib; Medicine; Everolimus; Pembrolizumab; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Quality of life (healthcare); Sorafenib; Cancer; Immunotherapy; Hepatocellular carcinoma","score_opus":0.05226541449896924,"score_gpt":0.333492476274445,"score_spread":0.28122706177547574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292002773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944813,0.003267496,0.00012428655,0.0002435149,0.00013449839,0.0005953762,0.0004758222,0.00001749414,0.00066013634],"genre_scores_gemma":[0.99617934,0.0011368529,0.00034264667,0.00034584443,0.00016990953,0.00073458796,0.0006014416,0.0000051990924,0.00048417956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991374,0.00049089757,0.000048531332,0.00013748452,0.00007182234,0.00011393954],"domain_scores_gemma":[0.99889,0.0002718565,0.00033149694,0.000054355223,0.00006149129,0.00039089454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014019315,0.001040782,0.002679576,0.00033937508,0.0004084352,0.00081573665,0.00072821486,0.0012222573,0.0031362858],"category_scores_gemma":[0.0013341557,0.0004958457,0.0026914238,0.00052476086,0.00080163655,0.00089269254,0.00050761114,0.0027694732,0.00039134294],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9765528,0.0053943703,0.0029685625,0.00042046752,0.0020110486,0.00002108904,0.0000431333,0.00038205003,0.0012747038,0.000037728532,0.0004030991,0.010490908],"study_design_scores_gemma":[0.85687613,0.12268055,0.01756246,0.00004250558,0.0014429264,0.00003829735,0.000041098385,0.0004268499,0.0002911445,0.000116176256,0.00046066457,0.000021310014],"about_ca_topic_score_codex":0.0016766901,"about_ca_topic_score_gemma":0.0031201567,"teacher_disagreement_score":0.0031362858,"about_ca_system_score_codex":0.001100407,"about_ca_system_score_gemma":0.0009685169,"threshold_uncertainty_score":0.010491908},"labels":[],"label_agreement":null},{"id":"W4392359260","doi":"10.17650/1726-9776-2023-19-4-32-43","title":"Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","year":2023,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Subgroup analysis; Carcinoma; Cancer; Immunotherapy; Meta-analysis","score_opus":0.03375832532127623,"score_gpt":0.3233777834645756,"score_spread":0.28961945814329937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392359260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995665,0.0017603599,0.00030935535,0.00019310636,0.00003183222,0.0006293791,0.0010265103,0.000016155926,0.0003683449],"genre_scores_gemma":[0.99572444,0.00034307042,0.0006336586,0.00024661855,0.00006703189,0.00089167705,0.001806106,0.000010121258,0.00027731084],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958656,0.0030461552,0.0001794749,0.0004017592,0.00034089855,0.00016606472],"domain_scores_gemma":[0.9968081,0.0009430957,0.0009956113,0.00037972158,0.00016072935,0.00071264914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077524954,0.0007172464,0.002049882,0.0003977921,0.00025125698,0.0007035288,0.0010337387,0.00077305845,0.0013651743],"category_scores_gemma":[0.003501352,0.00032524014,0.0040797265,0.00046942488,0.00049059896,0.00064909755,0.00075737777,0.001678431,0.00015811174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91687727,0.0022410385,0.054067645,0.00043217806,0.010090897,0.0000614033,0.000108177715,0.0015242214,0.0034565527,0.00015175957,0.0010449339,0.009943916],"study_design_scores_gemma":[0.4445333,0.15643016,0.37133893,0.00013101891,0.013624053,0.00028634907,0.00020458066,0.006549616,0.0030803927,0.00075090496,0.0029589233,0.000111683825],"about_ca_topic_score_codex":0.0009649667,"about_ca_topic_score_gemma":0.0026128886,"teacher_disagreement_score":0.0077524954,"about_ca_system_score_codex":0.00088517886,"about_ca_system_score_gemma":0.0012902331,"threshold_uncertainty_score":0.04099959},"labels":[],"label_agreement":null},{"id":"W4399047717","doi":"10.17650/1726-9776-2024-20-1-24-35","title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","year":2024,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.02240287845722777,"score_gpt":0.3040383810767318,"score_spread":0.28163550261950404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399047717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880634,0.004026802,0.00048052488,0.0005324067,0.00013503186,0.0024941124,0.002787214,0.000042291893,0.0014382906],"genre_scores_gemma":[0.98379934,0.0014473735,0.0014496826,0.0011232409,0.00033797737,0.004282668,0.006074653,0.000029669838,0.0014553989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983271,0.00097291404,0.00008931364,0.00023577551,0.00019368673,0.00018129953],"domain_scores_gemma":[0.9984647,0.00020712613,0.000413841,0.00014072041,0.00010744434,0.0006660796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004151849,0.0014036474,0.002897862,0.00048670472,0.0004917097,0.0010544268,0.0008550472,0.0010534709,0.0028202275],"category_scores_gemma":[0.0015133901,0.0005505599,0.0037279548,0.00053554284,0.00077065115,0.0010628225,0.00069973816,0.002492544,0.0006179776],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93120503,0.009964779,0.022127159,0.0005708773,0.004318489,0.000094532625,0.000121483165,0.0010882331,0.009276332,0.00018984299,0.0021223463,0.01892098],"study_design_scores_gemma":[0.70594084,0.20589857,0.077335365,0.000069161215,0.0027895372,0.00026639318,0.00011799315,0.001468277,0.0016646216,0.00050355005,0.0038883416,0.000057366087],"about_ca_topic_score_codex":0.00080906757,"about_ca_topic_score_gemma":0.0025834662,"teacher_disagreement_score":0.004151849,"about_ca_system_score_codex":0.00075225916,"about_ca_system_score_gemma":0.002188768,"threshold_uncertainty_score":0.021957338},"labels":[],"label_agreement":null},{"id":"W4399048033","doi":"10.17650/1726-9776-2024-20-1-79-93","title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","year":2024,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Subgroup analysis; Clinical trial; Cancer; Meta-analysis","score_opus":0.04692491571705633,"score_gpt":0.3929498133133948,"score_spread":0.3460248975963385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399048033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876068,0.008762767,0.0005425632,0.00030425127,0.00025087746,0.0010123726,0.00094915676,0.000023706898,0.0005475894],"genre_scores_gemma":[0.9958631,0.000982964,0.00040106222,0.0003218725,0.0001715578,0.00079560454,0.0010459486,0.00000972566,0.0004081959],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99486804,0.0035155807,0.0005275106,0.0005080985,0.00030129717,0.00027938292],"domain_scores_gemma":[0.99672866,0.0013693422,0.0008223912,0.0005374012,0.0001983239,0.0003439359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064308806,0.0015684151,0.004538947,0.00070178806,0.0003466278,0.001121482,0.000994357,0.0011730498,0.0025229778],"category_scores_gemma":[0.006507974,0.00052244036,0.008964583,0.0008859969,0.00064663735,0.0006225811,0.0008517031,0.0012157544,0.0002488047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9185725,0.000749467,0.029116493,0.0013452846,0.037045993,0.00014425367,0.00013656307,0.0006275046,0.0018511642,0.000121764664,0.0006431581,0.009645845],"study_design_scores_gemma":[0.6994426,0.061462134,0.15321055,0.00030620047,0.07604448,0.0003291312,0.00046477508,0.0036388312,0.0009358973,0.0011028964,0.0029089723,0.00015360999],"about_ca_topic_score_codex":0.002068602,"about_ca_topic_score_gemma":0.0047208285,"teacher_disagreement_score":0.0064308806,"about_ca_system_score_codex":0.0011212641,"about_ca_system_score_gemma":0.0013344848,"threshold_uncertainty_score":0.034010172},"labels":[],"label_agreement":null},{"id":"W4404673689","doi":"10.17650/1726-9776-2024-20-3-104-116","title":"Ureteroileal anastomosis-associated complications of radical cystectomy with ileal conduit in bladder cancer treatment","year":2024,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Cystectomy; Anastomosis; Electrical conduit; Bladder cancer; Medicine; Urology; Surgery; Urinary diversion; Cancer; Internal medicine","score_opus":0.029044409696966637,"score_gpt":0.32728550313827,"score_spread":0.29824109344130334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404673689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776995,0.0018459068,0.000085558255,0.00003139843,0.000008151426,0.000010221916,0.000018897172,0.0000015265927,0.00022839243],"genre_scores_gemma":[0.9994931,0.00034657304,0.00005810297,0.0000148496765,0.00001459978,0.000005672923,0.00003195071,4.2702976e-7,0.00003459674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957746,0.0001324144,0.000051502775,0.000051784886,0.00009602835,0.00009082959],"domain_scores_gemma":[0.99870324,0.00028029413,0.00063740066,0.000046411238,0.0000742113,0.00025841466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005761687,0.0001691954,0.00033411165,0.0004459758,0.00043053,0.0003704798,0.00023686301,0.0002789124,0.0007596416],"category_scores_gemma":[0.0015749413,0.00010361443,0.00036842507,0.0005392529,0.00028800996,0.000235661,0.0003199418,0.0003717379,0.00005644785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030257637,0.00008140044,0.9911306,0.0000590416,0.000044292752,0.0019552638,0.00008476415,0.000041906987,0.00040198897,0.000021637079,0.00005947511,0.0058171446],"study_design_scores_gemma":[0.000016990201,0.00067505834,0.9847615,0.000034746852,0.00006970089,0.013316954,0.00027267667,0.00016142146,0.00023633945,0.000048422833,0.00040053215,0.0000055572646],"about_ca_topic_score_codex":0.00046180194,"about_ca_topic_score_gemma":0.0010373935,"teacher_disagreement_score":0.0007596416,"about_ca_system_score_codex":0.0002862697,"about_ca_system_score_gemma":0.00048512832,"threshold_uncertainty_score":0.0030471087},"labels":[],"label_agreement":null}]}